Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye

Important Disclosures:

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announced on September 29, 2026, its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA's Office of New Drugs (OND) to appeal the agency's March 16, 2026, Complete Response Letter (CRL) denying approval of reproxalap for dry eye disease.

Key Investor Takeaways

• Aldeyra Therapeutics Inc. intends to submit an FDRR in Q4 2026 to appeal the March 2026 CRL for reproxalap in dry eye disease, based on data from nine clinical trials.
• The FDRR process allows formal appeal of FDA scientific decisions to higher management levels, with PDUFA target timelines of 30 days for response and possible meetings or panels.
• Investors should monitor the Q4 2026 OND meeting and subsequent decision for clarity on next steps, which could include resubmission or additional requirements.
• Cash position of US$45.1 million as of June 30, 2026, supports operations into 2029, providing runway through the appeal process.
• The appeal focuses on the totality of evidence rather than new trials, distinguishing it from prior CRL recommendations.

Latest News: Aldeyra's Appeal Plan

The company plans to submit the FDRR and hold a meeting with the OND in Q4 2026. Aldeyra has received three CRLs across one initial New Drug Application (NDA) and two resubmissions. The latest CRL cited insufficient evidence of effectiveness from the totality of nine adequate and well-controlled trials, five of which met all multiplicity-controlled primary endpoints. The firm updated its cash runway guidance to extend into 2029 based on US$45.1 million in cash and equivalents as of June 30, 2026.

"We remain steadfast in our commitment to working with the FDA to provide a novel therapeutic approach for the treatment of dry eye disease, a condition often regarded by patients and physicians as inadequately addressed by available therapies," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra Therapeutics. "Based on the activity of reproxalap across a number of clinical trial designs, and against a backdrop of FDA dry eye disease product approvals that have applied considerable discretion, we are optimistic in the outcome of the FDRR."

How the FDA Formal Dispute Resolution Request Process Works

The FDRR is an established FDA pathway under 21 CFR 10.75 and related regulations that lets a sponsor formally appeal a scientific or medical decision, such as a Complete Response Letter, when it cannot be resolved at the division level. In plain English, it is like asking a higher-level manager to review a lower-level decision. The sponsor submits a detailed request explaining why the original ruling should be overturned, supported by existing data or arguments.

For Prescription Drug User Fee Act products like reproxalap, the FDA aims to respond within 30 days of receipt, though actual timelines can stretch if the deciding official seeks extra information, consults experts, or convenes an advisory panel. A meeting with the OND is typically part of the process. If the appeal succeeds, the NDA can be resubmitted with any required additional information; if not, the company may need further trials or other steps.

Aldeyra's decision followed recent Type A and Type D meetings with the Division of Ophthalmology and Office of Specialty Medicine.

The Drug Development Market Needs R&D Funding

The rare-disease market has become an increasingly active area of drug development. The U.S. Food and Drug Administration (FDA) estimates that approximately 25 million to 30 million Americans live with a rare disease, encompassing roughly 10,000 rare diseases and conditions. The agency reported that exactly half of its 46 novel drug approvals in 2025 were for rare diseases, while 123 orphan new molecular entities were approved over the five years through 2025. The FDA also noted that small patient populations, heterogeneous disease characteristics, and limited understanding of natural disease progression can complicate rare-disease clinical trials.

Regulatory approaches are also evolving to address the challenges of rare-disease development. In 2025, the FDA introduced its Rare Disease Evidence Principles, outlining a framework for therapies targeting rare diseases with very small patient populations and significant unmet medical need driven by known genetic defects. The framework allows FDA and developers to consider evidence such as biomarkers, mechanistic data, pharmacodynamic measurements, natural-history studies, and nonclinical models alongside clinical trial results. For rare inherited cardiac disorders, these approaches can be relevant because the number of eligible patients may limit the feasibility of large, conventional randomized trials.

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

After Aldeyra's announcement, Yale Jen, Ph.D., of Laidlaw & Co. reiterated a "Buy" rating and US$13 target price.

At the same time, J. Edward Moreno of Sherwood News reported contradictory news on January 14, 2026, writing that, "In 2025, announced global biotech deals totaled US$228.4 billion, up from US$132.3 billion in 2024, data from Dealogic shows . . . Just two weeks into 2026, US$9.2 billion in deals have been announced."

According to Moreno, movement is expected in the sector: "As some of the most lucrative drugs lose exclusivity in the next few years, pharmaceutical giants are increasingly shopping around for biotechs to add to their portfolios — and they are more than happy to pay a hefty premium for the right company . . . For some Big Pharma companies, business development spending is now about equal to, or more than, research and development."

The shift toward business-development spending comes as some major pharmaceutical companies have reduced or reprioritized R&D spending. On March 25, 2026, BioSpace's Annalee Armstrong reported that, "R&D spending at the top 16 pharmaceutical companies declined by 3.6% overall in 2025, as many aggressively cut spending and refocused pipelines."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Analyst Coverage Looks to Appeal

After Aldeyra's announcement, Yale Jen, Ph.D., of Laidlaw & Co. reiterated a "Buy" rating and US$13 target price, writing that, "In our view, the FDRR is a logical next step since the reviewers in the agency may have strong pre-existing opinions on the study setup despite reproxalap was clearly demonstrated to be active in treating DED."

The analyst continued, arguing, "It is definitely worth a different set of eyes to reexamine the totality of clinical data to derive their own conclusions. We believe it will be straightforward if the appeal is granted. If so, a final label would be negotiated, and an NDA resubmission could take place afterward."

Marketbeat has also reported other recent analyst coverage, including: 

• On September 30, 2026, Matthew Caufield of H.C. Wainwright & Co. reiterated a "Neutral" rating with a price target of US$2.00.
• On September 29, 2026, Thomas Shrader of BTIG Research reiterated a "Buy" rating. 

What the Appeal Means for Aldeyra and Investors

The company believes that a successful appeal could reopen the path to approval without new trials, potentially accelerating the commercialization of reproxalap. The process carries uncertainty around timing and outcome, but it demonstrates Aldeyra's commitment to leveraging its clinical data package. Aldeyra also continues advancing other pipeline candidates, including ADX-2191 for primary vitreoretinal lymphoma.

Aldeyra remains focused on advancing its RASP modulator platform while navigating the regulatory appeal for reproxalap.

Ownership & Share Information¹

Aldeyra Therapeutics Inc. has a market cap of US$74.70 million, with 60.33 million shares outstanding. The company's 52-week range is US$1.07-US$5.93.

Institutions own 61.20% of shares, while Management & Insiders own 3.60% of shares. The remaining 35.20% of shares are Retail.

Frequently Asked Questions

Q: What is the FDRR, and how long does it take?

A: The Formal Dispute Resolution Request is the FDA's formal appeal mechanism for scientific disputes. Sponsors submit arguments to higher FDA officials; for user-fee products, the agency targets a response within 30 days, though meetings and decisions can extend into subsequent quarters depending on complexity.

Q: Why is Aldeyra pursuing this now?

A: Following Type A and Type D meetings, the company believes the existing nine-trial dataset supports approval and warrants higher-level review of the latest CRL.

Q: What happens if the appeal succeeds or fails?

A: Success could allow NDA resubmission without new studies. Failure may require additional data or trials, extending timelines and costs.

Q: How does this affect the company's cash runway?

A: Aldeyra extended guidance to 2029, covering the appeal period and ongoing pipeline work.

Q: What is a Complete Response Letter (CRL) from the FDA?
A: A Complete Response Letter is issued by the U.S. Food and Drug Administration when it determines that an application does not meet the requirements for approval in its current form. A CRL outlines the deficiencies that must be addressed before approval can be reconsidered.

Q: What is a New Drug Application (NDA)?
A: An NDA is the application a drug developer submits to the FDA seeking approval to market a new drug in the United States. It contains information on the drug's safety, effectiveness, manufacturing, labeling, and clinical development program.

Q: What is a PDUFA target action date?
A: A PDUFA target action date is the FDA's goal for completing its review of certain drug applications under the Prescription Drug User Fee Act. These timelines help establish when the agency expects to communicate an action on an application or regulatory matter.

Q: What is a Type A meeting with the FDA?
A: A Type A meeting is an FDA meeting intended to resolve important issues that may otherwise delay a drug development program. These meetings can address disputes, clinical holds, or other critical regulatory questions and provide drug developers an opportunity to discuss the agency's concerns directly.